Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Altair Therapeutics

Request full access

Antisense drug development for respiratory diseases

San Diego, United StatesFounded 2007Biotechnology

About Altair Therapeutics

Altair Therapeutics was a San Diego-based biopharmaceutical company founded in 2007 as a spin-out from Isis Pharmaceuticals (now Ionis Pharmaceuticals) and Thomas, McNerney & Partners. The company focused on discovering and developing antisense drugs to treat respiratory diseases like asthma and rhinitis. In May 2009, Dr. Joel Martin, a veteran life sciences investor and a member of the early scientific team at Isis Pharmaceuticals, was appointed as President and CEO.

The company's lead product candidate was AIR645, an inhaled, first-in-class antisense drug that targeted the alpha subunit of the IL-4 receptor, making it a dual inhibitor of IL-4 and IL-13, which are cytokines implicated in asthma. AIR645 was discovered by and licensed from Isis Pharmaceuticals. Altair Therapeutics successfully completed a Phase I multiple-dose safety and pharmacokinetic study of AIR645. The company raised a total of $23.5 million over two funding rounds, including a $17 million Series B round in November 2009. Key investors included Domain Associates, Thomas, McNerney & Partners, Forward Ventures, and Isis Pharmaceuticals.

Despite initial promise, Altair Therapeutics ceased operations in early 2011 after its sole drug candidate, AIR645, failed to show sufficient clinical activity in a Phase II trial for asthma. Following the trial failure, Isis Pharmaceuticals re-acquired Altair's assets. The company is now considered deadpooled or out of business.

Source: Dealroom company data

At a glance

Status
Closed
Open positions
None listed
Client focus
B2C
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Feb 2010 $17M $68M Domain Associates · Forward Ventures —
EARLY VC✓Equity / VC Nov 2009 $6.5M $26M Undisclosed —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Altair Therapeutics in the San Diego ecosystem

Live from Dealroom

The Altair Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Domain Associates
  • Forward Ventures
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Diego HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Altair Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Altair Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.